Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 30 Oct 2013 Ultrasound substudy results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 04 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Dec 2010 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.